- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Beth Wittmer Discusses Diet Restrictions With Neutropenia
Patients with neutropenia or at risk of it need to be cautious of their diet, said Beth Wittmer, RN, OCN, manager of care management at Florida Cancer Specialists and Research Institute.
Patients with neutropenia or at risk of it need to be cautious of their diet, said Beth Wittmer, RN, OCN, manager of care management at Florida Cancer Specialists and Research Institute.
Transcript
Getting people to modify their diets can be difficult. Is that the same with patients who develop neutropenia?
Not really, because once we warn them that those type of things [their diet] can cause potential bacteria, just like a common cold in somebody else could turn into pneumonia for them, making them really aware of the things that are high alerts. So, being cautious of their diet.
Once the white cells go back up, then I would say, “Hey, you’re good to go, you can have a salad. But during this time, when your white blood cells are low like this, just stay away and avoid that. You can have cooked vegetables, you could take canned fruit, but not eat it raw.”
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Read More
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
